in vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450
-
Published:2020
Issue:
Volume:
Page:S627-S636
-
ISSN:1802-9973
-
Container-title:Physiological Research
-
language:en
-
Short-container-title:Physiol Res
Author:
Špičáková A, Kraus P, Gucký T, Kryštof V, Strnad M, Bazgier V, Otyepka M, Kubíčková V, Poruba M, Rácová Z, Zapletalová I, Anzenbacher P1
Affiliation:
1. Department of Pharmacology, Faculty of Medicine, Palacký University Olomouc, Czech Republic. anzen@seznam.cz
Abstract
An evaluation of possible interactions with enzymes of drug metabolism (cytochromes P450, CYP) is an important part of studies on safety and, in general, on the properties of any drug or biologically active compound. The article is focused on the preliminary metabolic study of selected 2,6,9-trisubstituted purine kinase inhibitors with significant anticancer activities which we have developed. The compounds BP-21 and BP-117 represent strong CDK inhibitors and the compound BPA-302 was developed as selective FLT3-ITD kinase inhibitor. Here, emphasis is placed on interactions of these compounds with the nine most important forms of CYP to evaluate the possibility of inhibition of these enzymes. The possibility of their inhibitory effect was studied in vitro on selected human liver microsomal CYP enzymes. The most affected enzyme was CYP2C19. Its activity dropped to 22 % of its original value by BPA 302, to 13 % by BP-21 and to 6 % by BP-117 at the highest concentration tested (250 µmol·l 1). The results suggest that the metabolism of concomitantly administered drugs should not be significantly affected at lower doses. Molecular docking of BPA-302 indicated that it can bind to active site of both CYP2C19 and CYP2D6 enzymes above the heme cofactor corroborating the experimental data.
Publisher
Institute of Physiology of the Czech Academy of Sciences
Subject
General Medicine,Physiology
Reference35 articles.
1. ANZENBACHER P, ANZENBACHEROVÁ E: Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58: 737-747, 2001. https://doi.org/10.1007/PL00000897 2. ANZENBACHER P, ZANGER UM: Metabolism of Drugs and Other Xenobiotics. Wiley-VCH Verlag & Co KGaA, Germany, 2012. https://doi.org/10.1002/9783527630905 3. BRODNEY MA, BECK EM, BUTLER CR, BARREIRO G, JOHNSON EF, RIDDELL D, PARRIS K, NOLAN CE, FAN Y, ATCHISON K, GONZALES C, ROBSHAW AE, DORAN SD, BUNDESMANN MW, BUZON L, DUTRA J, HENEGAR K, LACHAPELLE E, HOU X, ROGERS BN, PANDIT J, LIRA R, MARTINEZ-ALSINA L, MIKOCHIK P, MURRAY JC, OGILVIE K, PRICE L, SAKYA SM, YU A, ZHANG Y, O'NEILL BT: Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem 58: 3223-3252, 2015. https://doi.org/10.1021/acs.jmedchem.5b00191 4. CICENAS J, KALYAN K, SOROKINAS A, STANKUNAS E, LEVY J, MESKINYTE I, STANKEVICIUS V, KAUPINIS A, VALIUS M: Roscovitine in cancer and other diseases. Ann Transl Med 3: 135, 2015. 5. CRESPI CL, CHANG TKH, WAXMAN DJ: Determination of CYP2C9-catalyzed diclofenac 4' hydroxylation by high-performance liquid chromatography. In: Cytochrome P450 Protocols. IR PHILLIPS, EA SHEPHARD (eds), Humana, Totowa, USA, 1998a, pp 109-113. https://doi.org/10.1385/1-59259-998-2:109
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|